Dose-escalation trial of Ad-MAGEA3 and MGA1-MAGEA3 in combination with pembrolizumab in NSCLC patients who have had at least one cycle of platinum based chemotherapy or one treatment of anti-PD-1/PD-L1 therapy. This evidence concerns the gene CUBN and non-small cell lung carcinoma.